

## **Pfenex Inc**

### **COMPANY AND PIPELINE OVERVIEW REPORT**

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 27-Apr-2015

#### **THOMSON REUTERS**

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)

## ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

## DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



**PLEASE NOTE:** the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Subsidiary Companies..... 11

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 16

[Return to Table of Contents](#)

# Pfenex Inc

## COMPANY OVERVIEW

Company Name	Pfenex Inc
Parent Company Name	Pfenex Inc
Website	<a href="http://www.pfenex.com/">http://www.pfenex.com/</a>
Country	US
Number of Drugs in Active Development	17
Number of Inactive Drugs	3
Number of Patents as Owner	5
Number of Patents as Third Party	0
Number of Deals	17
Key Indications	Inflammatory disease,Neutropenia,Bacillus anthracis infection,Cancer,Growth hormone deficiency,Multiple sclerosis,Plasmodium falciparum infection,Age related macular degeneration,Metastatic breast cancer,Non-Hodgkin lymphoma,Plasmodium infection,Rheumatoid arthritis,Unidentified indication
Key Target-based Actions	Interferon beta ligand,GCSF receptor agonist,GCSF ligand,GP IIb IIIa antagonist,Growth hormone ligand,Interferon alpha 2 ligand modulator,Interferon receptor modulator,TNF alpha ligand inhibitor,TNF antagonist,VEGF-A ligand inhibitor
Key Technologies	Biological therapeutic,Protein recombinant,Biosimilar product,Parenteral formulation unspecified,Injectable formulation,Antibody fragment,PEGylated formulation,Subcutaneous formulation,Antigen,Infusion,Intravenous formulation,Monoclonal antibody humanized

## COMPANY PROFILE

### SUMMARY

Pfenex Inc, headquartered in San Diego, CA is a leading biotechnology company focused on recombinant protein expression for a broad range of applications including therapeutic proteins, vaccines, research, reagents and biosimilars.

### ACQUISITIONS AND SPINOFFS

In April 2013, Pfenex, established an unnamed joint venture with Strides Acrolab subsidiary, Agila Biotech, to develop biosimilar products at Agila's Malaysian manufacturing facility. In July 2014, Strides disclosed that R&D programs for the biosimilar products were on track but further delays were expected in the manufacturing facility setup in Malaysia.

### FINANCIAL

In April 2015, the company priced its follow-on public offering of 6 million shares of its common stock at \$15.50 per share. Of the 6 million shares being offered, 2,610,000 were being offered by Pfenex and the remaining 3,390,000 shares were being offered by existing stockholders. Pfenex would not receive any proceeds from the shares sold by existing stockholders. The underwriters were granted a 30-day option to buy up to an additional 0.75 million shares of common stock from certain existing stockholders.

In September 2014, the shares began trading on the Russell Microcap and the Russell Global Indices.

In June 2014, Pfenex planned an IPO of common stock; in July 2014, the company priced its IPO of 8,333,333 common stock shares at a price of \$6.00 per share to the public and at that time, the underwriters were granted a 30-day option to purchase up to 1,250,000 additional common stock shares at the same price. The shares had begun trading under the symbol "PFNX" on the NYSE MKT; later that month, the offering was closed.

[Return to Table of Contents](#)



# COMPANY FINANCIALS

## SHARE INFORMATION

Close Price (USD)	14.61
Change (USD)	-1.19 (-7.53%)
Previous Close Price (USD)	15.80
Volume	411,554
52-Week High (USD)	19.95
52-Week Low (USD)	5.28
Date	27-Apr-2015
Exchange	NYSE AMEX(COMPOSITE)
Current Number of Shares Outstanding	20,376,974
Current Market Capitalization	324,256,401
EPS (Date Reported)	-0.47723

## STOCK PERFORMANCE




## MAJOR SHAREHOLDERS

[Return to Table of Contents](#)

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Dow Chemical Co	Corporation	United States	5,053,661	24.62	0	0	17-Apr-2015
Signet Healthcare Partners L.L.C.	Private Equity	United States	4,319,084	21.05	0	0	17-Apr-2015
Liang (Bertrand C)	Individual Investor	United States	561,980	2.74	-5,000	-0.01	17-Apr-2015
Lucy (Patrick K)	Individual Investor	United States	116,290	0.57	-1,500	-0.01	02-Apr-2015
Wagner Paul A	Individual Investor	United States	700	0	0	0	17-Apr-2015

## FINANCIAL PERFORMANCE



	2012	2013	2014		
Sales (USD M)	11.294	11.914	10.644		

[Return to Table of Contents](#)



	2012	2013	2014		
<b>Operating Income (USD M)</b>	-4.627	-6.697	-9.717		
<b>Net Income (USD M)</b>	-2.593	-4.062	-9.794		

### Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2014 Q4	2.019	-3.556	-3.574
2014 Q3	2.801	-2.476	-2.495
2014 Q2	3.266	-2.162	-2.63
2014 Q1	2.558	-1.523	-1.977
2013 Q3	1.989	-2.799	-2.12
2013 Q2	2.309	-1.945	-1.596
2013 Q1	3.385	-1.207	-1.134

### BALANCE SHEET

#### Assets (USD M)

	2012	2013	2014		
<b>Cash &amp; Short Term Investments</b>	9.966	5.204	45.722		
<b>Inventories - Total</b>	0.754	0.026	0.023		
<b>Current Assets - Total</b>	15.579	12.854	52.765		
<b>Property, Plant And Equipment - Net</b>	2.681	2.329	2.31		
<b>Other Assets - Total</b>	13.078	12.506	11.993		
<b>Total Assets</b>	32.932	31.813	71.023		

[Return to Table of Contents](#)



## Liabilities (USD M)

	2012	2013	2014		
Accounts Payable	2.012	1.804	2.042		
Short Term Debt & Current Portion Of Long Term Debt	0	0	3.862		
Current Liabilities - Total	5.541	6.01	7.776		
Long Term Debt	1.14	3.59	0.097		
Deferred Taxes	3.602	3.481	3.281		
Other Liabilities	0.009	0.003	-0.005		
Total Liabilities	10.292	13.084	11.149		

## Stockholders Equity (USD M)

	2012	2013	2014		
Minority Interest	0	0	0		
Preferred Stock	42.5	113.18	0		
Common Stock	0.002	0.002	0.021		
Treasury Stock	0	0	0		
Total Liabilities & Shareholders' Equity	32.932	31.813	71.023		

## FORECASTS

### EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.19	-1.23	-0.99
31-Dec-2016	-1.45	-1.45	-0.99
31-Dec-2017	-1.5	-1.5	-1

### Other Forecasts

Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015	0	-1.1	-23.9	8.65
31-Dec-2016	0	-1.83	-36.78	8.17
31-Dec-2017	0	-1.64	-42.03	9.25

[Return to Table of Contents](#)



SUBSIDIARY COMPANIES


Names
Pfenex/Stelis Joint Venture

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart



[Return to Table of Contents](#)

## Drugs by Indication Table


Indication	Active	Inactive	Total
Inflammatory disease	5	0	5
Infectious disease	4	1	5
Hematological disease	3	1	4
Neoplasm	3	1	4
Musculoskeletal disease	2	0	2
Immune disorder	2	0	2
Endocrine disease	2	0	2
Gynecology and obstetrics	1	0	1
Neurological disease	1	0	1
Ocular disease	1	0	1
Growth disorder	1	0	1
Metabolic disorder	1	0	1
Unidentified indication	1	0	1
Cardiovascular disease	0	1	1
Respiratory disease	0	1	1

[Return to Table of Contents](#)



## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 2 Clinical	1
Discovery	16
No Development Reported	3

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	7	0	0	0	7
Drug - Funding	4	0	1	0	5
Drug - Development/Commercialization License	1	0	0	0	1
Drug - Manufacturing/Supply	0	0	3	0	3

## CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
-------------------	---------	-----

[Return to Table of Contents](#)

## Trials by Condition Studied

Condition Studied	Ongoing	All
Ocular disease	1	2

## Trials by Phase

Phase	Ongoing	All
Phase 1	2	3

## Phase Definitions

### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	2	0	2
Endocrine disease	6	0	6
Gastrointestinal disease	4	0	4
Growth disorder	2	0	2
Hematological disease	2	0	2
Immune disorder	5	0	5
Musculoskeletal disease	1	0	1
Neoplasm	8	0	8
Genetic disorder	1	0	1
Metabolic disorder	3	0	3
Neurological disease	4	0	4
Respiratory disease	3	0	3
Infectious disease	13	0	13
Unidentified indication	2	0	2
Inflammatory disease	4	0	4

[Return to Table of Contents](#)



Gynecology and obstetrics	1	0	1
Dermatological disease	2	0	2

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

## PRODUCT PORTFOLIO DRUGS

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### PF-582

<b>Drug Name</b>	PF-582
<b>Key Synonyms</b>	ranibizumab
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Hospira Inc, Pfenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Phase 2 Clinical
<b>Active Indications</b>	Age related macular degeneration
<b>Target-based Actions</b>	VEGF-A ligand inhibitor
<b>Other Actions</b>	Angiogenesis inhibitor, Ocular antineovascularisation agent
<b>Technologies</b>	Monoclonal antibody humanized, Antibody fragment, Injectable formulation, Ophthalmic formulation, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	17-Mar-2015

### Px-563L

<b>Drug Name</b>	Px-563L
<b>Key Synonyms</b>	
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc, US Health and Human Services Department
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Bacillus anthracis infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antibacterial, Recombinant bacterial vector vaccine
<b>Technologies</b>	Injectable formulation, Quick release formulation, Antigen, Biological therapeutic, Parenteral formulation unspecified
<b>Last Change Date</b>	17-Mar-2015

[Return to Table of Contents](#)





**Px-533**

<b>Drug Name</b>	Px-533
<b>Key Synonyms</b>	
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	National Institutes of Health, Science Applications International Corp, Pfenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Plasmodium falciparum infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antiparasitic, Protein subunit vaccine
<b>Technologies</b>	Injectable formulation, Biological therapeutic, Parenteral formulation unspecified, Peptide
<b>Last Change Date</b>	17-Mar-2015

**interferon beta-1b biosimilar, Pfenex**

<b>Drug Name</b>	interferon beta-1b biosimilar, Pfenex
<b>Key Synonyms</b>	interferon beta-1b
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc
<b>Inactive Companies</b>	Pfenex/Stelis Joint Venture
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Multiple sclerosis
<b>Target-based Actions</b>	Interferon beta ligand, Interferon receptor modulator
<b>Other Actions</b>	Immunomodulator
<b>Technologies</b>	Subcutaneous formulation, Biological therapeutic, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	18-Mar-2015

[Return to Table of Contents](#)


### GCSF biosimilar, Pfenex/Sun

<b>Drug Name</b>	GCSF biosimilar, Pfenex/Sun
<b>Key Synonyms</b>	
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc, Sun Pharmaceutical Industries Ltd
<b>Inactive Companies</b>	Ranbaxy Laboratories Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Neutropenia
<b>Target-based Actions</b>	GCSF receptor agonist, GCSF ligand
<b>Other Actions</b>	Hematopoietic stimulant, Neutrophil stimulator
<b>Technologies</b>	Subcutaneous formulation, Intravenous formulation, Infusion, Biological therapeutic, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	26-Mar-2015

### somatropin biosimilar, Pfenex/Sun

<b>Drug Name</b>	somatropin biosimilar, Pfenex/Sun
<b>Key Synonyms</b>	somatropin
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc, Sun Pharmaceutical Industries Ltd
<b>Inactive Companies</b>	Ranbaxy Laboratories Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Growth hormone deficiency
<b>Target-based Actions</b>	Growth hormone ligand
<b>Other Actions</b>	
<b>Technologies</b>	Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	26-Mar-2015

[Return to Table of Contents](#)

### pegfilgrastim biosimilar, Pfenex

<b>Drug Name</b>	pegfilgrastim biosimilar, Pfenex
<b>Key Synonyms</b>	pegfilgrastim
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc
<b>Inactive Companies</b>	Pfenex/Stelis Joint Venture
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Neutropenia
<b>Target-based Actions</b>	GCSF receptor agonist
<b>Other Actions</b>	Hematopoietic stimulant, Neutrophil stimulator
<b>Technologies</b>	PEGylated formulation, Subcutaneous formulation, Biological therapeutic, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	17-Mar-2015

### undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis

<b>Drug Name</b>	undisclosed mAb biosimilar (non-Hodgkin's lymphoma/rheumatoid arthritis), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd, Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Rheumatoid arthritis, Non-Hodgkin lymphoma
<b>Target-based Actions</b>	B-lymphocyte antigen CD20 inhibitor
<b>Other Actions</b>	Anticancer monoclonal antibody, Anti-inflammatory
<b>Technologies</b>	Chimeric monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	20-Sep-2014

[Return to Table of Contents](#)



### undisclosed mAb biosimilar (cancer), Pfenex/Stelis

<b>Drug Name</b>	undisclosed mAb biosimilar (cancer), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd, Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Cancer
<b>Target-based Actions</b>	ErbB2 tyrosine kinase receptor inhibitor
<b>Other Actions</b>	Anticancer monoclonal antibody, Anticancer protein kinase inhibitor
<b>Technologies</b>	Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	20-Sep-2014

### undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis

<b>Drug Name</b>	undisclosed humanized VmAb biosimilar (metastatic breast cancer), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd, Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Metastatic breast cancer
<b>Target-based Actions</b>	ErbB2 tyrosine kinase receptor inhibitor
<b>Other Actions</b>	Anticancer monoclonal antibody
<b>Technologies</b>	Monoclonal antibody humanized, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	20-Sep-2014

[Return to Table of Contents](#)



### undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis

<b>Drug Name</b>	undisclosed mAb biosimilar (inflammatory diseases), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd, Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	TNF antagonist
<b>Other Actions</b>	Anti-inflammatory
<b>Technologies</b>	Monoclonal antibody human, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	20-Sep-2014

### undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis

<b>Drug Name</b>	undisclosed chimeric mAb biosimilar (inflammatory diseases), Pfenex/Stelis
<b>Key Synonyms</b>	
<b>Originator Company</b>	Inbiopro Solutions Pvt Ltd
<b>Active Companies</b>	Pfenex/Stelis Joint Venture
<b>Inactive Companies</b>	Inbiopro Solutions Pvt Ltd, Stelis Biopharma Pvt Ltd
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	TNF alpha ligand inhibitor
<b>Other Actions</b>	Anti-inflammatory
<b>Technologies</b>	Chimeric monoclonal antibody, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	20-Sep-2014

[Return to Table of Contents](#)



## PRIMALVAC

<b>Drug Name</b>	PRIMALVAC
<b>Key Synonyms</b>	
<b>Originator Company</b>	European Vaccine Initiative
<b>Active Companies</b>	INSERM, European Vaccine Initiative, Pfenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Plasmodium infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Prophylactic vaccine, Protein subunit vaccine
<b>Technologies</b>	Biological therapeutic, Protein recombinant
<b>Last Change Date</b>	20-Feb-2015

## PF-688

<b>Drug Name</b>	PF-688
<b>Key Synonyms</b>	certolizumab pegol
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	TNF alpha ligand inhibitor, TNF antagonist
<b>Other Actions</b>	Anti-inflammatory, TNF binding agent
<b>Technologies</b>	Monoclonal antibody humanized, Antibody fragment, PEGylated formulation, Injectable formulation, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	04-Dec-2013

[Return to Table of Contents](#)



### IFN alpha 2b biosimilar, Pfenex

<b>Drug Name</b>	IFN alpha 2b biosimilar, Pfenex
<b>Key Synonyms</b>	interferon alfa-2b
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Inflammatory disease
<b>Target-based Actions</b>	Interferon alpha 2 ligand modulator
<b>Other Actions</b>	Anti-inflammatory
<b>Technologies</b>	Biological therapeutic, Protein recombinant, Biosimilar product
<b>Last Change Date</b>	24-Jul-2014

### rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide

<b>Drug Name</b>	rPA vaccine (solid-dose injectable/ Glide SDI, anthrax), Pfenex / Glide
<b>Key Synonyms</b>	
<b>Originator Company</b>	Pfenex Inc
<b>Active Companies</b>	Pfenex Inc, Glide Pharmaceutical Technologies Ltd
<b>Inactive Companies</b>	
<b>Highest Status</b>	Discovery
<b>Active Indications</b>	Bacillus anthracis infection
<b>Target-based Actions</b>	
<b>Other Actions</b>	Antibacterial, Recombinant bacterial vector vaccine
<b>Technologies</b>	Injectable controlled release formulation, Antigen, Biological therapeutic, Parenteral formulation unspecified, Formulation solid
<b>Last Change Date</b>	10-Mar-2015

[Return to Table of Contents](#)

peginterferon beta 1b, Pfenex

Drug Name	peginterferon beta 1b, Pfenex
Key Synonyms	
Originator Company	Pfenex/Stelis Joint Venture
Active Companies	Pfenex Inc
Inactive Companies	Pfenex/Stelis Joint Venture
Highest Status	Discovery
Active Indications	Unidentified indication
Target-based Actions	Interferon beta ligand
Other Actions	
Technologies	PEGylated formulation, Biological therapeutic, Parenteral formulation unspecified, Protein recombinant
Last Change Date	18-Mar-2015

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

